A cloud-based decision support solution for diagnostic and prognostication of prostate cancer

News - March 2017

CADESS Medical selected to receive funding from Vinnova’s program for Innovative Start-Ups

Uppsala, Sweden March 14, 2017 – CADESS Medical AB today announces that the company will receive additional funding from Vinnova, the Swedish Agency for Innovation Systems. CADESS Medical was one of the start-ups from more than 650 applicants selected to share 35 MSEK of Vinnova’s support for Innovative Start-Ups.

Vinnova’s program for start-ups is intended to support the development of innovative products and services which can generate additional jobs and economic growth. CADESS Medical decision support system for diagnosis and prognostication of prostate cancer was one of the project ideas selected by an external panel. The company intends to use the funding to further develop its algorithms using state-of-the-art deep learning technology.

“We are happy and proud to receive Vinnova’s support and recognition. It confirms the level of innovation of our technology and the true clinical need we are committed to serve”, says Ingrid Carlbom, founder and CTO at CADESS Medical.

Prostate cancer is one of the most common cancers in men. Today malignancy grading of prostate cancer is highly subjective, resulting in most patients with localized prostate cancer receiving aggressive treatment that does not prolong life but often results in debilitating side effects and high costs for healthcare payers. CADESS Medicals technology can both improve patient outcome and reduce healthcare costs.

About CADESS Medical AB

CADESS Medical AB is a Swedish medical analytics company offering CADESS™, a cloud-based innovative digital pathology decision support solution based on image analysis for diagnosis and prognostication of cancer intended to improve patient outcome and reduce healthcare costs for prostate cancer. CADESS is the result of ten years of research at the Centre for Image Analysis, Department of Information Technology at Uppsala University, in collaboration with Uppsala University Hospital. For more information see www.cadessmedical.com.


For Further information, please contact:

Ingrid Carlbom, Chief Technology Officer
Tel: +46 (0) 73 048 20 25
E-mail: ingrid.carlbom@cadessmedical.com

Johan von Heijne, Investor Relations and Executive Advisor
Tel: +46 705 95 15 10
E-mail: johan.vonheijne@cadessmedical.com